UroGen Pharma Shares Outstanding History (URGN)
UroGen Pharma reported 48.4M shares outstanding at the end of fiscal 2025.
View full UroGen Pharma company overviewUroGen Pharma annual shares outstanding history
| Fiscal year | Period ended | Shares outstanding | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 48.4M | 6.1M | +14.49% |
| 2024 | 2024-12-31 | 42.2M | 9.7M | +29.98% |
| 2023 | 2023-12-31 | 32.5M | 9.4M | +40.47% |
| 2022 | 2022-12-31 | 23.1M | 666,958 | +2.97% |
| 2021 | 2021-12-31 | 22.5M | 295,204 | +1.33% |
| 2020 | 2020-12-31 | 22.2M | 1.1M | +5.43% |
| 2019 | 2019-12-31 | 21.0M | 4.8M | +29.67% |
| 2018 | 2018-12-31 | 16.2M | 2.5M | +17.91% |
| 2017 | 2017-12-31 | 13.8M | 11.4M | +496.40% |
| 2016 | 2016-12-31 | 2.3M | — | — |
UroGen Pharma quarterly shares outstanding
| Fiscal quarter | Period ended | Shares outstanding | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 48.9M | 2.7M | +5.78% |
| Q1 2026 | 2026-03-31 | 48.7M | 2.6M | +5.65% |
| Q4 2025 | 2025-12-31 | 48.4M | 6.1M | +14.49% |
| Q3 2025 | 2025-09-30 | 46.8M | 4.6M | +10.88% |
| Q2 2025 | 2025-06-30 | 46.2M | 5.0M | +12.22% |
| Q1 2025 | 2025-03-31 | 46.1M | 10.0M | +27.61% |
| Q4 2024 | 2024-12-31 | 42.2M | 9.7M | +29.98% |
| Q3 2024 | 2024-09-30 | 42.2M | 11.3M | +36.74% |
| Q2 2024 | 2024-06-30 | 41.2M | 17.7M | +75.20% |
| Q1 2024 | 2024-03-31 | 36.1M | 12.7M | +54.12% |
| Q4 2023 | 2023-12-31 | 32.5M | 9.4M | +40.47% |
| Q3 2023 | 2023-09-30 | 30.9M | 7.8M | +34.09% |
| Q2 2023 | 2023-06-30 | 23.5M | 770,726 | +3.39% |
| Q1 2023 | 2023-03-31 | 23.4M | 758,300 | +3.34% |
| Q4 2022 | 2022-12-31 | 23.1M | 666,958 | +2.97% |
| Q3 2022 | 2022-09-30 | 23.0M | 606,479 | +2.71% |
| Q2 2022 | 2022-06-30 | 22.7M | 373,358 | +1.67% |
| Q1 2022 | 2022-03-31 | 22.7M | 401,827 | +1.80% |
| Q4 2021 | 2021-12-31 | 22.5M | 295,204 | +1.33% |
| Q3 2021 | 2021-09-30 | 22.4M | 333,413 | +1.51% |
| Q2 2021 | 2021-06-30 | 22.4M | 353,237 | +1.61% |
| Q1 2021 | 2021-03-31 | 22.3M | 1.1M | +5.03% |
| Q4 2020 | 2020-12-31 | 22.2M | 1.1M | +5.43% |
| Q3 2020 | 2020-09-30 | 22.1M | 1.1M | +5.38% |
| Q2 2020 | 2020-06-30 | 22.0M | 1.2M | +5.52% |
| Q1 2020 | 2020-03-31 | 21.2M | 454,592 | +2.19% |
| Q4 2019 | 2019-12-31 | 21.0M | 4.8M | +29.67% |
| Q3 2019 | 2019-09-30 | 20.9M | 4.8M | +30.07% |
| Q2 2019 | 2019-06-30 | 20.8M | 5.0M | +31.52% |
| Q1 2019 | 2019-03-31 | 20.8M | 5.3M | +34.15% |
| Q4 2018 | 2018-12-31 | 16.2M | 2.5M | +17.91% |
| Q3 2018 | 2018-09-30 | 16.1M | 13.8M | +598.35% |
| Q2 2018 | 2018-06-30 | 15.9M | — | — |
| Q1 2018 | 2018-03-31 | 15.5M | — | — |
| Q4 2017 | 2017-12-31 | 13.8M | — | — |
| Q4 2016 | 2016-12-31 | 2.3M | — | — |
UroGen Pharma shares outstanding trends
Over the last five reported fiscal years, UroGen Pharma's shares outstanding moved from 22.2M to 48.4M, a change of 26.2M. The latest reported quarter, Q2 2026, shows 48.9M.
What shares outstanding means
Shares outstanding is the number of common shares held by investors at a reporting-period end. The count can change because of stock issuance, repurchases, conversions, acquisitions, or stock splits.
SEC-reported period-end shares
TickerStat displays period-end common shares from SEC filings and adjusts older values to the current share basis when SEC-reported stock-split conversion ratios are available. Values remain as reported when no split ratio is available. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review UroGen Pharma filings at SEC.gov ↗